Analysts Conflicted on These Healthcare Names: Icon plc (NASDAQ: ICLR), Zimmer Biomet Holdings (NYSE: ZBH) and Ultragenyx (NASDAQ: RARE)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Icon plc (NASDAQ: ICLR), Zimmer Biomet Holdings (NYSE: ZBH) and Ultragenyx (NASDAQ: RARE).

Icon plc (NASDAQ: ICLR)

Jefferies analyst David Windley reiterated a Buy rating on Icon plc (NASDAQ: ICLR) on July 27 and set a price target of $122. The company’s shares closed on Friday at $102.84, close to its 52-week high of $107.72.

According to TipRanks.com, Windley is a top 25 analyst with an average return of 25.1% and a 80.7% success rate. Windley covers the Services sector, focusing on stocks such as Quintiles Transnational, Quest Diagnostics Inc, and WellCare Health Plans.

Currently, the analyst consensus on Icon plc is Strong Buy and the average price target is $110, representing a 7.0% upside.

In a report issued on July 27, Credit Suisse also maintained a Buy rating on the stock with a $105 price target.
Zimmer Biomet Holdings (NYSE: ZBH)

Jefferies analyst Raj Denhoy reiterated a Buy rating on Zimmer Biomet Holdings (NYSE: ZBH) on July 27 and set a price target of $143. The company’s shares closed on Friday at $123.78.

According to TipRanks.com, Denhoy is a top 100 analyst with an average return of 16.2% and a 72.4% success rate. Denhoy covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Varian Medical Systems, and Edwards Lifesciences.

Currently, the analyst consensus on Zimmer Biomet Holdings is Moderate Buy and the average price target is $135.29, representing a 9.3% upside.

In a report issued on July 12, Guggenheim also upgraded the stock to Buy with a $157 price target.
Ultragenyx (NASDAQ: RARE)

In a report issued on July 28, Eun Yang from Jefferies reiterated a Hold rating on Ultragenyx (NASDAQ: RARE), with a price target of $69. The company’s shares closed on Friday at $66.99.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 5.7% and a 50.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, DBV Technologies SA – American, and Achillion Pharmaceuticals.

Ultragenyx has an analyst consensus of Strong Buy, with a price target consensus of $88.14.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.